DUBLIN and CHICAGO, May 25, 2018 /PRNewswire/ -- Iterum Therapeutics plc (NASDAQ:ITRM), a clinical-stage pharmaceutical company developing anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens, today announced the pricing of its initial public offering of...
from PR Newswire: //https://ift.tt/2INv55h
No comments:
Post a Comment